Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CPN1 | P15169 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680019 | 0.83 | PIK3CD (0.45) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL27517757 | 0.80 | EPHX2 (0.44) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL15722292 | 0.79 | PIK3CD (0.42) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL4590995 | 0.79 | DPP4 (0.44) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL25123952 | 0.79 | CYP1A2 (0.42) | EPHX1CYP1A2MEN1ALDH1A1KMT2A | |
| SCHEMBL2319485 | 0.78 | CPN1 (0.44) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL7883168 | 0.78 | PIK3CD (0.46) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL2317281 | 0.78 | CPN1 (0.44) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL2316879 | 0.78 | CPN1 (0.44) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL22875128 | 0.77 | MEN1 (0.39) | MEN1ALDH1A1KMT2ACPN1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | PIK3CD 146/4885EPHX2 3033/4885EPHX1 2887/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CD 146/4885EPHX2 3033/4885EPHX1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.